Skip to main content
. Author manuscript; available in PMC: 2014 Feb 5.
Published in final edited form as: Pancreas. 2008 Mar;36(2):168–172. doi: 10.1097/MPA.0b013e318158a4d2

FIGURE 1.

FIGURE 1

The oncogenic mutation spectrum of patient no. 1. Our data showed that KRAS, BRAF, and PIK3CA mutations can often coexist in the same patient, whereas mutations of ERBB2 and EGFR are rare in IPMN/IPMC.